Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)

Publication | Closed Access

DOI

Citations

References

2021

Year

Lucia Musacchio, Vanda Salutari, Sandro Pignata, Elena Ioana Braicu, David Cibula, Nicoletta Colombo, Jean‐Sébastien Frenel, Flora Zagouri, Vittoria Carbone, Viola Ghizzoni,

International Journal of Gynecological Cancer